Months after FDA slam, AbbVie buys Parkinson’s disease drugmaker Mitokinin

Among pharma majors, AbbVie has not been a company closely associated with the central nervous system (CNS) category.

However, Thursday’s deal to acquire neurodegenerative disease specialist Mitokinin appears to be one of several recent moves by the company in that direction.